Ranolazine: A novel metabolic modulator for the treatment of chronic stable...
Current medical therapy for chronic stable angina (CSA) is targeted at reducing the frequency of anginal symptoms and improving exercise tolerance by increasing myocardial oxygen supply and/or reducing...
View ArticleEconomic analysis of a medication assistance program for ambulatory care...
Objective: Pharmacy-managed medication assistance programs (MAP) have the potential to recoup losses incurred by the pharmacy department, but whether this offsets the personnel cost of the program has...
View ArticleRanolazine: A novel metabolic modulator for the treatment of chronic stable...
Current medical therapy for chronic stable angina (CSA) is targeted at reducing the frequency of anginal symptoms and improving exercise tolerance by increasing myocardial oxygen supply and/or reducing...
View ArticleEconomic analysis of a medication assistance program for ambulatory care...
Objective: Pharmacy-managed medication assistance programs (MAP) have the potential to recoup losses incurred by the pharmacy department, but whether this offsets the personnel cost of the program has...
View ArticleRanolazine: A novel metabolic modulator for the treatment of chronic stable...
Current medical therapy for chronic stable angina (CSA) is targeted at reducing the frequency of anginal symptoms and improving exercise tolerance by increasing myocardial oxygen supply and/or reducing...
View ArticleRanolazine: A novel metabolic modulator for the treatment of chronic stable...
Current medical therapy for chronic stable angina (CSA) is targeted at reducing the frequency of anginal symptoms and improving exercise tolerance by increasing myocardial oxygen supply and/or reducing...
View ArticleEconomic analysis of a medication assistance program for ambulatory care...
Objective: Pharmacy-managed medication assistance programs (MAP) have the potential to recoup losses incurred by the pharmacy department, but whether this offsets the personnel cost of the program has...
View Article
